{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:32:34Z","timestamp":1793223154425,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012781","name":"Merck Sharp and Dohme K.K.","doi-asserted-by":"publisher","award":["MISP 101310"],"award-info":[{"award-number":["MISP 101310"]}],"id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015652","name":"Barts Charity","doi-asserted-by":"publisher","award":["MGU0504"],"award-info":[{"award-number":["MGU0504"]}],"id":[{"id":"10.13039\/100015652","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lanepe.2026.101808","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:54:31Z","timestamp":1787784871000},"page":"101808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Epidemiology, temporal trends, and fibrosis risk stratification in metabolic dysfunction-associated steatotic liver disease in UK primary care: a population-based cohort and nested case\u2013control study"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9741-3538","authenticated-orcid":false,"given":"Huei-Tyng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Temperley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3891-5914","authenticated-orcid":false,"given":"William","family":"Alazawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2026.101808_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.lanepe.2026.101808_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.lanepe.2026.101808_bib3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.lanepe.2026.101808_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cpt.2766","article-title":"Contribution of real-world evidence in European medicines agency's regulatory decision making","volume":"113","author":"Bakker","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.lanepe.2026.101808_bib6","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence - what is it and what can it tell us?","volume":"23","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2026.101808_bib7","article-title":"Real-world evidence in metabolic dysfunction-associated steatotic liver disease (MASLD): insights, challenges, and future directions","volume":"62","author":"Huang","year":"2026","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2026.101808_bib8","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical practice research datalink (CPRD) aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.lanepe.2026.101808_bib9","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000386","article-title":"The future of International Classification of Diseases coding in steatotic liver disease: an expert panel Delphi consensus statement","volume":"8","author":"Hagstr\u00f6m","year":"2024","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.lanepe.2026.101808_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12916-018-1103-x","article-title":"Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease","volume":"16","author":"Alexander","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.lanepe.2026.101808_bib11","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/HEP.0000000000000664","article-title":"Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings","volume":"79","author":"Lee","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.lanepe.2026.101808_bib12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/HEP.0000000000000604","article-title":"National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature","volume":"79","author":"Lee","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.lanepe.2026.101808_bib13","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple non-invasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.lanepe.2026.101808_bib14","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.lanepe.2026.101808_bib16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.lanepe.2026.101808_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1022460","article-title":"Non-alcoholic fatty liver disease is not a causal risk factor for psoriasis: a Mendelian randomization study of 108,835 individuals","volume":"13","author":"N\u00e4slund-Koch","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.lanepe.2026.101808_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2337\/dc17-1590","article-title":"Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission","volume":"41","author":"Wild","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lanepe.2026.101808_bib19","article-title":"A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis","volume":"54","author":"Lazarus","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2026.101808_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanepe.2026.101808_bib21","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2337\/dci24-0094","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association","volume":"48","author":"Cusi","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lanepe.2026.101808_bib22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S2213-8587(21)00116-9","article-title":"Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK","volume":"9","author":"Carr","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.lanepe.2026.101808_bib24","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMra2403308","article-title":"Non-invasive assessment of liver fibrosis","volume":"393","author":"Castera","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101808_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254939","article-title":"Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results","volume":"16","author":"Halfon","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.lanepe.2026.101808_bib26","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.numecd.2024.05.016","article-title":"Fibrosis-4 score for screening of metabolic dysfunction-associated steatotic liver disease (MASLD): data from a population-based sample in Tuscany","volume":"34","author":"Silverii","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.lanepe.2026.101808_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-058967","article-title":"Liver blood marker testing in UK primary care: a UK wide cohort study, 2004-2016","volume":"12","author":"Scutt","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.lanepe.2026.101808_bib28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jhep.2019.05.033","article-title":"Intelligent liver function testing (iLFT): a trial of automated diagnosis and staging of liver disease in primary care","volume":"71","author":"Dillon","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanepe.2026.101808_bib29","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/S0168-8278(24)00448-3","article-title":"OS-007-YI Intelligent liver function test 5 years on-the evolution of an intelligent platform","volume":"80","author":"Leith","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanepe.2026.101808_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-066493","article-title":"Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review: PRELUDE1 prospective cohort study protocol","volume":"13","author":"Brindley","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.lanepe.2026.101808_bib31","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/jgh.70080","article-title":"Epidemiology of metabolic dysfunction\u2013associated steatotic liver disease in South Asian ethnicities: a systematic review and meta-analysis","volume":"40","author":"James","year":"2025","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.lanepe.2026.101808_bib32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/flgastro-2017-100865","article-title":"Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent","volume":"9","author":"De Silva","year":"2018","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.lanepe.2026.101808_bib33","doi-asserted-by":"crossref","first-page":"101735","DOI":"10.1016\/j.jhepr.2026.101735","article-title":"Diabetes and obesity reduce FIB-4 accuracy in MASLD referral pathways","volume":"8","author":"Shaheen","year":"2026","journal-title":"JHEP Rep"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:39:25Z","timestamp":1793219965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226002206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"alternative-id":["S2666776226002206"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101808","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology, temporal trends, and fibrosis risk stratification in metabolic dysfunction-associated steatotic liver disease in UK primary care: a population-based cohort and nested case\u2013control study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101808"}}